Histamine H3 receptor agonist- and antagonist-evoked vacuous chewing movements in 6-OHDA-lesioned rats occurs in an absence of change in microdialysate dopamine levels

European Journal of Pharmacology

Volumn 552, Issue 1-3, 2006, Pages 46-54

  Nowak, Przemysław ^a   Dabrowska, Joanna ^a   Bortel, Aleksandra ^a   Biedka, Izabela ^a   Szczerbak, Grazyna ^a   Słomian, Grzegorz ^a   Kostrzewa, Richard M ^b   Brus, Ryszard ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b East Tennessee State University   (United States)

Author keywords

6 OHDA lesioned rat; Catalepsy; Dopamine D1 receptor; Histamine H3 receptor; Microdialysis; Priming; Striatum; Vacuous chewing movement

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; HISTAMINE H3 RECEPTOR AGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; IMETIT; OXIDOPAMINE; THIOPERAMIDE; ANTIHISTAMINIC AGENT; DIALYSIS FLUID; DRUG DERIVATIVE; HISTAMINE AGONIST; HISTAMINE H3 RECEPTOR; IMIDAZOLE DERIVATIVE; PIPERIDINE DERIVATIVE; THIOUREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CATALEPSY; CONTROLLED STUDY; CORPUS STRIATUM; DIALYSATE LEVEL; DOPAMINE BRAIN LEVEL; IN VIVO STUDY; MALE; MASTICATION; MICRODIALYSIS; MOTOR DYSFUNCTION; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE MICROARRAY; VACUOUS CHEWING MOVEMENT; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; METABOLISM; MOTOR ACTIVITY; NEWBORN; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; STEREOTYPY; WISTAR RAT;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; 2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; ANIMALS, NEWBORN; CATALEPSY; CORPUS STRIATUM; DIALYSIS SOLUTIONS; DOPAMINE; HISTAMINE AGONISTS; HISTAMINE ANTAGONISTS; IMIDAZOLES; MALE; MASTICATION; MICRODIALYSIS; MOTOR ACTIVITY; OXIDOPAMINE; PIPERIDINES; RATS; RATS, WISTAR; RECEPTORS, HISTAMINE H3; STEREOTYPED BEHAVIOR; THIOUREA;

EID: 33750433933     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.08.092     Document Type: Article

References (61)

1. 3 receptors in the brain of 6-hydroxydopamine-lesioned rats. Eur. J. Neurosci. 11 (2000) 3823-3832
2. Anichtchik O.V., Rinne J.O., Kalimo H., and Panula P. An altered histaminergic innervation of the substantia nigra in Parkinson's disease. Exp. Neurol. 163 (2000) 20-30
3. Arias-Monatano J.A., Floran B., Garcia M., Aceves J., and Young J.M. Histamine H(3) receptor-mediated inhibition of depolarization-induced, dopamine D(1) receptor-dependent release of [(3)H]-gamma-aminobutryic acid from rat striatal slices. Br. J. Pharmacol. 133 (2001) 165-171
4. 2 dopamine receptors in the monkey striatum. J. Comp. Neurol. 418 (2000) 22-32
5. Betarbet R., and Greenamyre J.T. Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP. Exp. Neurol. 189 (2004) 393-403
6. Brown R.E., Stevens D.R., and Haas H.L. The pathophysiology of brain histamine. Prog. Neurobiol. 63 (2001) 637-672
7. Breese G.R., Knapp D.J., Criswell H.E., Moy S.S., Papadeas S.T., and Blake B.L. The neonate-6-hydroxydopamine-lesioned rat: a model for clinical neuroscience and neurobiological principles. Brain Res. Brain Res. Rev. 48 (2005) 57-73
8. Bruno J.P., Byrnes E.M., and Johnson B.J. Independent mediation of unconditioned motor behavior by striatal D1 and D2 receptors in rats depleted of dopamine as neonates. Psychopharmacology (Berl.) 122 (1995) 85-94
9. Brus R., Kostrzewa R.M., Perry K.W., and Fuller R.W. Supersensitization of the oral response to SKF 38393 in neonatal 6-hydroxydopamine-lesioned rats is eliminated by neonatal 5,7-dihydroxytryptamine treatment. J. Pharmacol. Exp. Ther. 268 (1994) 231-237
10. Brus R., Szkilnik R., Nowak P., and Kostrzewa R.M. Nitro-l-arginine attenuates SKF 38393-induced oral activity in neonatal 6-hydroxydopamine-lesioned rats. Acta Neurobiol. Exp. (Wars) 57 (1997) 283-287
11. Brus R., Nowak P., Sokola A., Kostrzewa R.M., and Shani J. Behavioral and biochemical effects of new central dopamine D3 and D4 receptor antagonists in rats. Pharmacol. Rev. Commun. 12 (2002) 39-59
12. 2 agonist-enhancement of locomotor activity in 6-hydroxydopamine-lesioned rats. Neurotox. Res. 5 (2003) 329-338
13. 3 receptor antagonist, attenuates stimulant-induced locomotor activity in the mouse. Eur. J. Pharmacol. 259 (1994) 107-114
14. Criswell H., Mueller R.A., and Breese G.R. Priming of D1-dopamine receptor responses: long-lasting behavioral supersensitivity to a D1-dopamine agonist following repeated administration to neonatal 6-OHDA-lesioned rats. J. Neurosci. 9 (1989) 125-133
15. 3 receptor: characterization and autoradiographic localization in rat brain. Synapse 8 (1991) 144-151
16. Duncan G.E., Criswell H.E., McCown T.J., Paul I.A., Mueller R.A., and Breese G.R. Behavioral and neurochemical responses to haloperidol and SCH-23390 in rats treated neonatally or as adults with 6-hydroxydopamine. J. Pharmacol. Exp. Ther. 243 (1987) 1027-1034
17. Elverfors A., and Nissbrandt H. Effects of d-amphetamine on dopaminergic neurotransmission; a comparison between the substantia nigra and the striatum. Neuropharmacology 31 (1992) 661-670
18. Farzin D., and Attarzadeh M. Influence of different histamine receptor agonists and antagonists on apomorphine-induced licking behavior in rat. Eur. J. Pharmacol. 404 (2000) 169-174
19. Ganellin C.R., Hosseini S.K., Khalaf Y.S., Tertiuk W., Arrang J.M., Garbarg M., Ligneau X., and Schwartz J.C. Design of potent non-thiourea H3-receptor histamine antagonists. J. Med. Chem. 38 (1995) 3342-3350
20. Garbarg M., Arrang J.M., Rouleau A., Ligneau X., Tuong M.D., Schwartz J.C., and Ganellin C.R. S-[2-(4-imidazolyl)ethyl]isothiourea, a highly specific and potent histamine H3 receptor agonist. J. Pharmacol. Exp. Ther. 263 (1992) 304-310
21. 3H]GABA release from depolarization-stimulated slices of rat substantia nigra pars reticulata. Neuroscience 80 (1997) 241-249
22. 3 agonist immepip and systemic apomorphine elicit ipsilateral turning behaviour in naive rats, but reduce contralateral turning in hemiparkinsonian rats. Behav. Brain Res. 154 (2004) 409-415
23. Gong L., Kostrzewa R.M., Fuller R.W., and Perry K.W. Supersensitization of the oral response to SKF 38393 in neonatal 6-OHDA-lesioned rats is mediated through a serotonin system. J. Pharmacol. Exp. Ther. 261 (1992) 1000-1007
24. Huotari M., Kukkonen K., Liikka N., Potasev T., Raasmaja A., and Mannisto P.T. Effects of histamine H(3)-ligands on the levodopa-induced turning behavior of hemiparkinsonian rats. Parkinsonism Relat. Disord. 6 (2000) 159-164
25. Kay G.G., and Harris A.G. Loratadine: a non-sedating antihistamine. Review of its effects on cognition, psychomotor performance, mood and sedation. Clin. Exp. Allergy 29 (1999) 147-150
26. Kikuchi de Beltran K., Koshikawa N., Saigusa T., Watanabe K., Koshida Y., and Kobayashi M. Cholinergic/dopaminergic interaction in the rat striatum assessed from drug-induced repetitive oral movements. Eur. J. Pharmacol. 214 (1992) 181-189
27. Kostrzewa R.M. Dopamine receptor supersensitivity. Neurosci. Biobehav. Rev. 19 (1995) 1-17
28. 1 receptors mediate enhanced oral activity after neonatal 6-OHDA. Pharmacol. Biochem. Behav. 39 (1991) 677-682
29. Kostrzewa R.M., and Neely D. Enhanced pilocarpine-induced oral activity responses in neonatal 6-OHDA treated rats. Pharmacol. Biochem. Behav. 45 (1993) 737-740
30. Kostrzewa R.M., and Kastin A.J. Tyr-MIF-1 attenuates development of tolerance to spiperone-induced catalepsy in rats. Brain Res. Bull. 31 (1993) 707-712
31. Kostrzewa R.M., Kostrzewa J.P., and Brus R. Dopaminergic denervation enhances susceptibility to hydroxyl radicals in rat neostriatum. Amino Acids 19 (2000) 183-199
32. Kostrzewa R.M., Kostrzewa J.P., Nowak P., Kostrzewa R.A., and Brus R. Dopamine D2 agonist priming in intact and dopamine-lesioned rats. Neurotox. Res. 6 (2004) 457-462
33. Kostrzewa R.M., Nowak P., Kostrzewa J.P., Kostrzewa R.A., and Brus R. Peculiarities of l-DOPA treatment of Parkinson's disease. Amino Acids 28 (2005) 157-164
34. Kostrzewa R.M., Kostrzewa J.P., Brus R., and Nowak P. Proposed animal model of severe Parkinson's disease: neonatal 6-hydroxydopamine lesion of dopaminergic innervation of striatum. J. Neural Transm. 70 (2006) 277-279 (Suppl)
35. Kostrzewa, R.M., Nowak, P., Kostrzewa, J.P., Brus, R., (in press). Modeling tardive dyskinesia: predictive 5-HT(2O) receptor antagonist treatment. Neurotox. Res. 10.
36. Magnusson O., Nilsson L.B., and Westerlund D. Simultaneous determination of dopamine, DOPAC and homovanillic acid. Direct injection of supernatants from brain tissue homogenates in a liquid chromatography-electrochemical detection system. J. Chromatogr. 221 (1980) 237-247
37. Moore D.J., West A.B., Dawson V.L., and Dawson T.M. Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 28 (2005) 57-87
38. Morisset S., Rouleau A., Ligneau X., Gbahou F., Tardivel-Lacombe J., Stark H., Schunack W., Ganellin C.R., Schwartz J.C., and Arrang J.M. High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature 408 (2000) 860-864
39. Morisset S., Pilon C., Tardivel-Lacombe J., Weinstein D., Rostene W., Betancur C., Sokoloff P., Schwartz J.C., and Arrang J.M. Acute and chronic effects of methamphetamine on tele-methylhistamine levels in mouse brain: selective involvement of the D(2) and not D(3) receptor. J. Pharmacol. Exp. Ther. 300 (2002) 621-628
40. 3 receptor antagonists potentiate methamphetamine self-administration and methamphetamine-induced accumbal dopamine release. Neuropsychopharmacology 29 (2004) 705-717
41. 1., receptor behavioral responsitivity following selective lesions of the striatal patch compartment during development. Brain Res. Dev. Brain Res. 60 (1991) 105-113
42. Nowak P., Brus R., Oœwiêcimska J., Sokoła A., and Kostrzewa R.M. 7-Nitroindazole enhances amphetamine-evoked dopamine release in rat striatum. An in vivo microdialysis and voltammetric study. J. Physiol. Pharmacol. 53 (2002) 251-263
43. Nowak P., Labus L., Stabryła J., Durczok A., Nowicka J., and Shani J. Biogenic amines in striatum of rats that had been treated with ethanol, and their brains later stored in different temperatures. Recept. Channels 9 (2003) 339-342
44. Nowak P., Kostrzewa R.M., Kwiecinski A., Bortel A., Labus L., and Brus R. Neurotoxic action of 6-hydroxydopamine on the nigrostriatal dopaminergic pathway in rats sensitized with d-amphetamine. J. Physiol. Pharmacol. 56 (2005) 325-333
45. Ossowska K., Wardas J., Smialowska M., Kuter K., Lenda T., Wieronska J.M., Zieba B., Nowak P., Dabrowska J., Bortel A., Kwiecinski A., and Wolfarth S. A slowly developing dysfunction of dopaminergic nigrostriatal neurons induced by long-term paraquat administration in rats: an animal model of preclinical stages of Parkinson's disease?. Eur. J. Neurosci. 22 (2005) 1294-1304
46. Paxinos G., and Watson C. The Rat Brain in Stereotaxtic Coordinates. 2nd edition (1986), Academic Press, Sydney
47. 3 receptor ligands in experimental models of anxiety and depression. Psychopharmacology (Berl.) 142 (1999) 215-220
48. Pillot C., Ortiz J., Heron A., Ridray S., Schwartz J.C., and Arrang J.M. Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, potentiates neurochemical and behavioral effects of haloperidol in the rat. J. Neurosci. 22 (2002) 7272-7280
49. 3 receptors in rat brain areas. Neuroscience 52 (1993) 169-189
50. 2 histamine receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 360 (1999) 552-557
51. 2 receptors in adult rat neostriatum after neonatal dopamine denervation: quantitative data from ligand binding, in situ hybridization and iontophoresis. Neuroscience 57 (1993) 635-648
52. 3 receptors in the striatum and substantia nigra after 6-hydroxydopamine-induced denervation of dopaminergic neurons: an autoradiographic study. Neurosci. Lett. 178 (1994) 19-22
53. 3-receptors following destruction of the ascending dopaminergic neurones. Br. J. Pharmacol. 118 (1996) 585-592
54. 3 receptor activation inhibits dopamine D1 receptor-induced cAMP accumulation in rat striatal slices. Neurosci. Lett. 364 (2004) 179-184
55. Takeda H., Matsumiya T., and Shibuya T. Detection and identification modes for the highly sensitive and simultaneous determination of various biogenic amines by coulometric high-performance liquid chromatography. J. Chromatogr. 515 (1990) 265-278
56. Toyota H., Dugovic C., Koehl M., Laposky A.D., Weber C., Ngo K., Wu Y., Lee D.H., Yanai K., Sakurai E., Watanabe T., Liu C., Chen J., Barbier A.J., Turek F.W., Fung-Leung W.P., and Lovenberg T.W. Behavioral characterization of mice lacking histamine H(3) receptors. Mol. Pharmacol. 62 (2002) 389-397
57. Waddington J.L. Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology (Berl.) 101 (1990) 431-447
58. Wieland K., Bongers G., Yamamoto Y., Hashimoto T., Yamatodani A., Menge W.M., Timmerman H., Lovenberg T.W., and Leurs R. Constitutive activity of histamine H(3) receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H(3) antagonists. J. Pharmacol. Exp. Ther. 299 (2001) 908-914
59. 3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. Pharmacol. Ther. 103 (2004) 1-20
60. Zetterstrom T., Sharp T., and Ungerstedt U.F. Further evaluation of the mechanism by which amphetamine reduces striatal dopamine metabolism: a brain dialysis study. Eur. J. Pharmacol. 132 (1986) 1-9
61. 3 receptor antagonists and antipsychotic drugs. Brain Res. 31 (2005) 142-149